Recursion Pharmaceuticals
clinical dosage hypothesis rescue of may impact tumor progression and or restore sensitivity in cancers driven by loss recursion differentiation rescues tumor suppressor genes and and are negative regulators of signaling both proteins form part of the destruction complex strong clustering suggests map recapitulation of this biology insight from novel insight around established | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
116 of 143
Related slides by other companies
AN2 Therapeutics
Investor Presentation
March 2025
macro analysis as continuous score reinforces outcomes observed in respiratory domain | AN2 Therapeutics
Mink Therapeutics
IPO
October 2021
phase clinical trial focused in solid tumors | Mink Therapeutics
AN2 Therapeutics
Investor Presentation
February 2025
macro analysis as continuous score reinforces outcomes observed in respiratory domain | AN2 Therapeutics
Nuvalent
IPO
July 2021
planned first in human clinical trial of in positive and other advanced solid tumors | Nuvalent
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights